Snapshot · The Peter Attia Drive
A Mendelian randomization study of ~350,000 Finnish biobank participants found each standard deviation increase in genetically predicted grip strength was linked to a 3% reduction in all-cause mortality.
Where this was said
At 21:15 · chapter starts 20:30
The obvious objection to the mortality data is confounding: maybe stronger people live longer simply because they were already healthier to begin with. Peter takes this seriously, acknowledging genuine bidirectionality — health enables training, and training improves health. But Mendelian randomization offers a cleaner signal. By using a polygenic score for grip strength (genetic variants associated with being naturally stronger) as a proxy, researchers in a Finnish biobank study of roughly 300,000–350,000 participants were able to disentangle cause from correlation [1] — Peter Attia "A Mendelian randomization study of 350,000 Finnish biobank participants used genetic scores as proxies for grip strength and found partial …" 20:15 . Each standard deviation increase in the genetic grip strength score was linked to a 7% reduction in vascular dementia risk, 6% lower obesity risk, 5% lower type 2 diabetes risk, 4% lower risk of major adverse cardiovascular events, and 3% lower all-cause mortality. Peter interprets this as partial causality: the benefits of strength are not entirely explained by pre-existing health, but the effect sizes in real-world cohorts are amplified by the health-enables-training loop.
Animals first sensed light 540 million years ago, triggering an evolutionary acceleration known as the Cambrian explosion within 10 million years.
It is estimated that half of all cortical activity in the human brain is involved in visual function, underscoring vision's central role in intelligence.
Cognitive neuroscience literature shows that by age 6, humans can recognize tens of thousands of different object categories — far more data than early AI systems were trained on.
Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, making an unknown mechanism a meaningful early red flag for any compound.
Even compounds that clear preclinical testing often fail in humans: 30 to 50% of drugs entering phase 1 trials do not advance to phase 2, frequently because human behavior differs from animal models.
More than 80% of published BPC-157 research comes from a single academic group whose researchers have IP and commercial interests connected to the molecule, limiting independent replication.
Roughly 100 peptide drugs are already FDA-approved, about 150 more are in clinical trials, and 600–700 are in preclinical development, underscoring the legitimacy of peptide science broadly.
The scientist who discovered BPC-157 refused to disclose the screening method used to identify the compound and has never fully published the parent protein sequence — what Peter Attia calls 'scientific trust me, bro.'
The brain's visual, auditory, and motor cortices light up nearly identically whether an experience is real or imagined, making visualization a form of actual neural training.
We use essential and analytics cookies to run Vuci. To understand how the site is used: Privacy Policy.
Install Vuci on your phone
Add it to your home screen for a faster, app-like experience.
Install Vuci on your phone
Tap the Share button, then “Add to Home Screen”.
A new version is available
Reload to get the latest Vuci.